Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Albert Oriol et al.|The Lancet Oncology|2019Cited by 383
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Heinz Ludwig et al.|The Lancet Oncology|2021Cited by 266
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios Α. Dimopoulos, Evangelos Terpos, Giampaolo Merlini et al.|The Lancet Oncology|2023Cited by 120